The Systemic Nature of Severe Traumatic Brain Injury

Detailed Description

Severe traumatic brain injury (sTBI) is a devastating condition for which no targeted therapies currently exist. Current acute management strategies are largely focused on stabilizing cerebral physiology rather than addressing the molecular mechanisms responsible for injury progression.

The initial traumatic injury and subsequent secondary injury processes, including neuroinflammation, neurotoxicity, and disruption of the blood-brain barrier (BBB), may contribute to a robust autoimmune response. Pilot studies in adolescents have demonstrated activation of a strong immune response characterized by BBB disruption and autoantibody formation. This response may contribute to short- and long-term inflammatory sequelae, including exacerbation of the initial injury, progression to chronic neurodegenerative disease, increased disability, and mortality.

Alterations in the gut-brain axis may serve as a potential source of increased immunogenicity and subsequent autoantibody formation. The primary objective of this project is to define the immune mechanisms involved in the interaction between brain injury and alterations in gut permeability through the gut-brain axis.

Metabolomics comprehensively profiles and quantifies small-molecule metabolites produced by cells, tissues, and microorganisms, allowing for the evaluation of metabolic pathways and their roles in specific biological processes. Although several omics studies have characterized time-dependent changes in adults and experimental models, comparable studies using multi-omics approaches in sTBI remain limited. This represents an important gap in understanding the biological mechanisms involved in injury progression.

Lipids are essential to cellular function because of their roles in membrane composition, cellular signaling, and energy metabolism, particularly within the brain. Lipidomics, a subfield of metabolomics, identifies and quantifies lipids across cell types, organs, and organisms. Investigation of cellular lipid pathways and networks may provide important insight into the molecular mechanisms underlying traumatic brain injury (TBI). Emerging lipidomic studies suggest that circulating and central nervous system (CNS)-derived lipid signatures are associated with injury severity, BBB disruption, and long-term neurodegenerative risk. Therefore, lipidomics may provide important information for the comprehensive evaluation of sTBI pathogenesis.

The gut-brain axis is a bidirectional communication network between the gastrointestinal tract and CNS. It has been implicated in the pathophysiology of several neurodegenerative disorders and, more recently, in TBI. Following sTBI, rapid alterations may occur in gastrointestinal motility, epithelial barrier integrity, immune signaling, and microbial community structure. Collectively, these changes may result in gut dysbiosis and increased intestinal permeability, potentially due to diffuse mucosal barrier dysfunction.

Maintenance of gastrointestinal mucosal integrity requires coordinated interactions between the epithelial lining, associated cellular junctions, and immune mechanisms that regulate permeability and absorption. In contrast, the BBB is highly regulated and relatively impermeable under normal physiological conditions. Following brain injury, BBB permeability may increase, allowing the entry of molecules that would not typically cross the barrier. These peripheral disturbances may contribute to neuroinflammation, oxidative stress, and neurodegeneration. However, the precise mechanisms underlying these interactions remain unclear and are a primary focus of this study.

To identify the cells and molecular pathways involved in these alterations, single-cell RNA sequencing (scRNA-seq) will be combined with global metabolomics, with particular emphasis on identifying unique gut-derived metabolites, including bacterial products and food antigens that are not typically detected in serum. Single-cell RNA sequencing will be used to identify circulating cell types and clonal activation. These findings will be integrated with metabolomic data to further characterize the mechanisms through which increased gut permeability may contribute to neurotoxicity following sTBI.

This multi-omics approach is intended to develop a comprehensive model of the cellular and molecular mechanisms involved in the interaction between the gut and brain following sTBI. Ultimately, these findings may identify potential therapeutic targets aimed at reducing immune activation and attenuating secondary and tertiary brain injury.